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Abstract
Background: Routine ART programme statistics generally only provide information about individuals who start
treatment. We aimed to investigate the outcome of those who are eligible but do not start ART in the Malawi
programme, factors associated with this dropout, and reasons for not starting treatment, in a prospective cohort
study.
Methods: Individuals having a first screening visit at the ART clinic at Karonga District Hospital, northern Malawi,
between September 2005 and July 2006 were interviewed. Study follow-up to identify treatment outcomes was
conducted at the clinic and in the community. Logistic regression models were used to identify factors associated
with dropout before ART initiation among participants identified as clinically eligible for ART.
Results: 88 participants eligible for ART at their first screening visit (out of 633, 13.9%) defaulted before starting
ART. Participants with less education, difficulties in dressing, a more delayed ART initiation appointment, and mid-
upper arm circumference (MUAC) < 22 cm were significantly less likely to have visited the clinic subsequently.
Thirty-five (58%) of the 60 participants who defaulted and were tracked at home had died, 21 before their ART
initiation appointment.
Conclusions: MUAC and reported difficulties in dressing may provide useful screening indicators to identify sicker
ART-eligible individuals at high risk of dropping out of the programme who might benefit from being brought
back quickly or admitted to hospital for observation. Individuals with less education may need adapted health
information at screening. Deaths of ART-eligible individuals occurring prior to ART initiation are not included in
routine programme statistics. Considering all those who are eligible for ART as a denominator for programme
indicators would help to highlight this vulnerable group, in order to identify new opportunities for further
improving ART programmes.
Background
In Malawi, adult HIV prevalence has stabilised at about
14% since the late 1990s [1]. Scale-up of antiretroviral
treatment (ART) began in Malawi in 2004, with initial
selection of 60 hospitals across the country to provide
broad geographical coverage [2,3]. The Malawi national
ART programme follows a public health model focusing
on ‘service delivery to all who need it’ [4]. A generic, fixed-
dose combination treatment (Triommune) with stavudine,
lamivudine and nevirapine is available as first line treat-
ment and given free of charge to eligible patients. An alter-
native first line treatment option is available if an
individual has unacceptable side effects to Triommune.
Second line treatment is available if an individual is consid-
ered to have failed first line treatment. According to
national guidelines, individuals are eligible for ART in
Malawi if, upon physical examination and history during a
screening clinic visit, they were assessed to be in stage III/
IV, or stage II with a CD4 count < 250 cells/mm
3.
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This guardian is subsequently allowed to collect medicines
monthly on behalf of the patient on condition that the
patient attends the clinic every three months.
The ART clinic at Karonga District Hospital opened
in June 2005, through a partnership between the Malawi
Ministry of Health and Karonga Prevention Study. The
clinic was assessed to be a ‘medium burden’ clinic by
the Ministry of Health and allowed to enroll 50 new
patients a month onto ART. A number of patients
already on ART in other districts were also transferred
in, most as soon as the clinic opened. Transfers-in were
additional to the monthly target. The ART clinic was
open for screening visits three days a week, with treat-
ment visits on the other two days. Ideally the group
counseling session occurred 2-3 days after staging, with
ART initiation one week later. However, this varied
depending on the length of the waiting list. Two
appointments a week were kept ‘open’ to fast track indi-
viduals who were very sick but deemed stable enough to
initiate immediately. No CD4 tests were available at the
hospital laboratory. Therefore, eligibility for ART initia-
tion in Karonga was determined using WHO stage. In
this district, in common with most areas of Malawi,
diagnostic facilities were also limited and it was not pos-
sible to obtain microbiological, histological or imaging
support for WHO Stage 4 diagnoses. The alternative
first line and second line treatment options were only
available for the northern districts at Mzuzu hospital,
approximately three hours by road from Karonga Dis-
trict Hospital.
The Karonga ART clinic used the simple standardised
national documentation system designed by the National
ART programme for the providers of ART in the public
sector, to generate routine key statistics. This nation-
wide system has demonstrated that the programme has
been successful in terms of retention and survival
a m o n gt h o s ew h os t a r tA R T[ 5 ] .H o w e v e r ,l i t t l ei s
known in Malawi about the outcome of those who are
eligible but do not make it into the programme [6] or
their reasons for not starting treatment [7]. In this
paper we measure the extent of loss of ART-eligible
individuals between screening and ART initiation and
identify risk factors associated with this loss.
Methods
In addition to data available from the national docu-
mentation system, additional data were collected for this
study in the screening clinic and at home visits. All
patients attending a first screening visit at the Karonga
ART clinic between September 2005 and July 2006 were
eligible for inclusion in this study and were assigned a
unique ID number independent of the government
programme number series (which is only assigned to
those who start ARVs). On recruitment into the study,
all participants were asked to provide written consent
for the additional data collection. During the screening
visit, socio-demographic and clinical data were collected
(see Additional file 1 for clinical questions) including:
age, sex, occupation, marital status, level of education,
village of residence, HIV stage, weight and height, mid-
upper arm circumference (MUAC), and indicators for
activities of daily living (dressing, washing, eating/drink-
ing, toileting, walking 100 m).
A clinician staged each individual’s HIV disease and, if
ART-eligible, assessed their readiness to start treatment
based on their understanding of the treatment benefits,
willingness to adhere and to continue even if they felt
better, and their ability to attend the clinic regularly (in
terms of costs, that they lived in the district etc). Some
individuals were considered ART-eligible, however they
were too sick to start immediately and needed to be sta-
bilized before starting ART. Others had medical contra-
indications and were told to come back later; they were
taking ketaconazole, or were in the first trimester of preg-
nancy, or were in the intensive phase of TB treatment
(although this has since changed as a contra-indication).
For individuals who were told that they were not yet
clinically eligible on the first visit, clinicians would make
appointments if they wanted to review the person again,
otherwise they were asked to return when they had
symptoms.
Follow-up of those who were identified as eligible for
treatment but did not initiate ART was conducted
between February and December 2006. Tracking was
conducted by the same team that were following treat-
ment defaulters from the Karonga ART clinic. Given
limited resources, priority was given to tracking treat-
ment defaulters which sometimes delayed/prevented the
tracking of non-initiators. Deaths were reported by rela-
tives to staff at the clinics or during tracking visits.
Ethics approval was given by the Malawi National
Health Sciences Research Committee and the London
School of Hygiene & Tropical Medicine, UK.
Statistical Analysis
All analyses were conducted in Stata 10.0 (Stata Corp.,
College Station, Texas, USA). Logistic regression models
were used to identify factors associated with dropout
before ART initiation among participants identified as
clinically eligible for ART at their first screening visit.
Age and education level were considered as categorical
variables. Malawi’s education system provides 8 years of
primary and 4 years of secondary school. Students may
study in any of the three major local languages for most
of the first 4 years of primary school after which English
becomes the medium. Thus, for our models we grouped
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of primary education, those with 5+ years of primary
education but never attended secondary school, and
those who attended at least one year of secondary or
continued through further education. The distance
between each participant’s village and the ART clinic
was calculated using GPS coordinates pre-recorded for
each local village, and a group of indicators representing
distance between residence and the ART clinic were
considered in the models. Height and weight measures
were used to calculate body mass index (BMI) and a
binary indicator of chronic energy deficiency (CED,
using a BMI cutoff of <18.5) was considered in the ana-
lyses. Mid-upper arm circumference (MUAC) was used
to create a separate indicator of CED; (grade 1 or higher
vs no CED) defined as MUAC < 22.0 cm for females
and <23.0 cm for males. The questions asking about dif-
ficulties in daily living were based on self-care and
mobility questions from the activities and participation
domains section of the WHO International Classifica-
tion of Functioning, Disability and Health [8]. Initially,
each question was considered in the analysis using a
separate indicator to represent functioning (any diffi-
culty vs no difficulty) in a particular activity. In addition,
a composite indicator was created to represent reported
difficulty in any activity vs no reported difficulties. Indi-
cators were used to represent four 3-month periods dur-
ing study recruitment in order to investigate whether
the characteristics of individuals at the time of first pre-
sentation changed with the length of time since the
clinic opened (eg. with different WHO stage). A sepa-
rate set of indicators was used to represent whether
an ART initiation appointment was given to the ART-
eligible individual for 0-7 days, 8-30 days or 31+ days
after their screening visit. These categories were chosen
to reflect the target of giving ART initiation appoint-
ments within a week of screening, vs a delay in the
appointment date, and splitting that delay into less than
or more than 1 month.
For the multivariate models, we used a stepwise pro-
cedure to determine the final model considering all vari-
ables significant in the univariate analyses, sex and age,
and each separate indicator of daily functioning.
Among those not clinically eligible at first presenta-
tion, descriptive statistics were used to document how
many returned for a second or third screening visit and
how many were found to be ART-eligible at the later
visits.
Results
759 individuals attended the screening clinic for the first
time during this period and 730 (96.2%) were interviewed
and consented to participate. Twenty-two patients were
missed by the study team during busy clinic sessions and
seven refused. The median age of the participants at first
presentation was 36.7 years, (IQR 30.9 - 44.3), with 9 <18
years old (median 14.9, range 13.3-15.8 years). Forty per-
cent (40%) were male, 43% reported farming as their
occupation, and 55% were assessed to be in WHO stage
IV. Forty-eight percent (48%) were currently married and
28% were widowed. Only 27% had ever attended second-
ary school. Almost universally (>99%), participants
reported having sought care within the last 6 months
from a hospital/health centre or a traditional healer, a
private practitioner or a combination of these.
Six hundred and thirty-three (633/730, 86.7%) were
told they were clinically eligible for treatment (Figure 1),
including six individuals who were in WHO stage II but
had a CD4 count < 250 cells/mm
3 established through
their participation in a research study. However, 17 of
these participants were not ready to start treatment
because they were too sick (N = 13) or had contra-indi-
cations (N = 4). Of the 616 participants identified as
ready to start treatment, 532 (86.4%) did so, a median of
22 days (IQR 12-29 days) after the screening visit, with
10% starting after more than 40 days. In addition, 13 of
the 17 clinically eligible participants initially advised not
to start treatment started later (Figure 1), a median of
22 days (IQR 13-27 days) after the screening visit. This
leaves 88 (13.9%) individuals who were clinically eligible
for ART after the first visit, but who did not return to
clinic. Table 1 shows the distribution of selected charac-
teristics among those clinically eligible to start treatment
at their first screening visit and odds ratio (OR) esti-
mates of association between these factors and dropout
before starting ART. In the final multivariate model,
there was a significantly higher risk of dropout asso-
ciated with lower education, grade 1 or higher chronic
energy deficiency (CED), difficulty in dressing, a more
delayed ART initiation appointment, and being screened
in the later calendar periods of the study. A test for lin-
ear trend in calendar period was not statistically signifi-
cant (c
2 test for trend was 3.27 on 1 degree freedom,
p = 0.07). There was no significant association with age,
sex, current marital status, distance of residence from
clinic, or WHO stage, even in univariate models. In a
univariate model, BMI < 18.5 was significantly asso-
ciated with a significantly higher odds of dropout, how-
ever this did not remain significant in the multivariate
model that included an indicator of CED using MUAC.
An alternative model to the final model considered the
composite indicator of difficulty in any daily functioning
instead of difficulty in dressing and found the composite
indicator not to be significantly associated with the odds
of dropout (likelihood ratio test p = 0.65).
Forty-eight (49%) of the 97 individuals who were told
that they were not yet clinically eligible on the first visit
were invited by the clinician to return for a second
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visit appointments were not captured in the study data-
base. Sixteen of these 48 returned for a second screen-
ing, a median of 61 days (IQR 25, 100) after their first
screening. In contrast, 15 of the 49 participants asked to
return when they had symptoms returned a median of
80 days (IQR (30, 173) after their first screening visit.
Thus overall, 31 participants returned for a second
screening, and 25 of them were eligible for ART. One of
these 25 was too sick and one had contra-indications so
were not started on ART immediately, and neither
returned, and three other individuals did not return to
the ART clinic. The remaining 20 started ART. Among
the 6 who were not clinically eligible at their second
visit to the screening clinic, 3 returned for a third visit
at which time one was clinically eligible for ART and
started treatment.
Combining the first, second and third screening visits,
93 eligible participants (out of 659, 14%) defaulted
before starting ART. We tracked 60 (65%) of these at
home, a median 55 days after they had missed their
ART appointment (IQR: 35, 83). Thirty-five (58%) had
died, 21 before their ART initiation appointment and
the others soon after (median 19 days after appoint-
ment, IQR 7, 47). Three individuals had left the area
and two could not be traced. Of the 20 individuals
found alive at follow-up, 4 reported illness as the main
reason for not attending, 8 reported lack of money for
transport, 4 could not find a suitable guardian, 2 were
too busy, one felt well after the screening visit, and one
gave no reason. One of the individuals who reported ill
health as the reason for not attending at the first follow-
up visit, was found through a second home visit to have
died soon after. Twenty one (64%) of the 33 not sought
Figure 1 Outcome of first screening visit and ART initiation status.
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Page 4 of 8Table 1 Univariate and multivariate logistic regression models for odds of dropout after first screening visit despite
being clinically eligible to start ART1
Characteristic N (% dropout) Univariate Hazard Ratios
2, 95% CI Multivariate Hazard Ratios
2, 95% CI
Sex : Female 369 (14) 1.0
Male 263 (14) 0.99 (0.62, 1.57)
Age (yrs): <30 137 (14) 1.0
30-<40 255 (15) 1.12 (0.62, 2.03)
40+ 240 (12) 0.85 (0.46, 1.59)
WHO stage : IV 404 (13) 1.0
II
3 or III 228 (15) 1.23 (0.77, 1.95)
Education
None 40 (30) 2.89 (1.36, 6.11)** 3.10 (1.40, 6.86)**
1-4 years Primary 85 (19) 1.56 (0.83, 2.94) 1.57 (0.81, 3.02)
5+ years Primary 325 (13) 1.0 1.0
Secondary or higher 174 (8) 0.59 (0.31, 1.11) 0.67 (0.35, 1.29)
Missing 8 (38) 4.04 (0.93, 17.5) 5.83 (1.21, 28.1)
Occupation
Farmer 267 (17) 1.0*
Other occupation 197 (9) 0.48 (0.27, 0.86)
Not working 163 (14) 0.75 (0.43, 1.30)
Missing 5 (20) 1.20 (0.13, 10.99)
Current marital status (1 missing)
Married 299 (13) 1.0
Divorced 132 (14) 1.09 (0.60, 1.96)
Widowed 171 (14) 1.06 (0.61, 1.82)
Single 29 (14) 0.96 (0.34, 3.13)
Distance to clinic
<2 km 100 (13) 1.0
2-5 km 148 (7) 0.54 (0.23, 1.25)
> = 5 km 375 (14) 1.13 (0.59, 2.16)
Missing 9 (100) -
Body Mass Index
No CED 299 (10) 1.0*
CED4 326 (17) 1.93 (1.20, 3.12)
Missing 7 (29) 3.72 (0.69, 20.1)
MUAC
No CED CED5 349 (10) 283 (18) 1.0** 2.02 (1.27, 3.20) 1.0** 1.91 (1.17, 3.12)
Difficulty in dressing
None 556 (13) 1.0* 1.0*
Slight/greater difficulty 76 (22) 2.00 (1.10, 3.63) 2.34 (1.22, 4.50)
Difficulty in daily functioning
6
None 251 (13) 1.0
Slight/greater difficulty 381 (14) 1.09 (0.68, 1.74)
Period of first presentation
Sept -November 2005 124 (6) 1.0** 1.0*
Dec 2005 - Feb 2006 200 (17) 3.42 (1.47, 7.99) 3.81 (1.59, 9.15)
March - May 2006 224 (14) 2.68 (1.14, 6.29) 2.31 (0.94, 5.68)
≥ June 1, 2006 84 (18) 3.63 (1.41, 9.35) 2.48 (0.82, 7.52)
Timing of ART initiation appt given relative to screening visit
0-7 days 81 (7) 1.0* 1.0**
8-30 days 439 (13) 1.90 (0.79, 4.57) 2.61 (1.03, 6.64)
31+ days 112 (21) 3.23 (1.25, 8.35) 5.04 (1.71, 14.8)
1 N = 632 since mid-upper arm circumference was included in the final multivariate model and one individual was missing this variable (they were not seen
again at the clinic).
2 likelihood ratio test p value; *p < 0.05, **p < 0.01, ***p < 0.001.
3Six had a low CD4 count recorded.
4 WHO recommends the use of BMI < 18.5 for grade 1 of higher chronic energy deficiency (CED).
5 WHO recommends the use of sex specific MUAC cut off points of <22 cm for female and <23 cm for men for CED.
6 Any difficulty in washing or dressing oneself, toileting, eating/drinking, or walking 100 m w/out a stick, in response to the question “On an average day in the
last week, how difficult has it been for you to perform the following activities without any kind of assistance at all?”.
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after mid-June 2006, i.e. shortly before the end of the
study.
Discussion
We show that in this ART programme 14% of individuals
who would potentially have benefited from treatment did
not start ART. This is similar to the estimate (16.4%)
from a retrospective cohort study in South Africa [9] but
lower than the 25.5% reported by a retrospective cohort
study in southern Malawi [7]. Similar to the experience
of TB programmes, exclusion from analysis of patients
who die or are lost between presentation and starting
treatment may potentially bias programme estimates of
treatment outcomes, making them difficult to interpret
and potentially misleading [10,11].
In a context where CD4 counts are not available,
MUAC and reported difficulties in dressing may provide
useful screening indicators to identify sicker ART-eligi-
ble individuals at high risk of dropping out of the pro-
gramme who might benefitf r o mb e i n gb r o u g h tb a c k
quickly or admitted to hospital for observation. The
finding that WHO stage IV was not associated with a
higher odds of dropout before ART initiation compared
to those in WHO stage III was unexpected. This may
reflect the specific policy of keeping some appointments
each week available for sicker patients, or represent an
increased effort by individuals to seek treatment because
they were sicker. Higher odds of defaulting among
lower educated individuals has been shown elsewhere in
Africa and may suggest that the content, amount and
complexity of information given to patients during the
screening visit may need to be adapted [12].
The significant positive association between dropout
and length of delay from screening to the initiation
appointment is consistent with a Cambodian study [13].
Now that the service at Karonga is well established,
delays between screening and starting treatment are no
longer a prominent feature. This is likely to change if
criteria are altered to enable people to start treatment at
an earlier stage, and may require a two stream service
to ensure that those in more clinical need are not
affected by waiting lists. The finding that participants
enrolled in the later calendar periods of the study had a
significantly higher odds of dropout compared to those
recruited in the earliest period of the study may be due
to particularly motivated patients coming for screening
as soon as the clinic opened.
Previous work by our group has suggested that ART
eligibility based on clinical staging criteria alone may
miss up to two-thirds of those considered eligible using
criteria based on clinical staging and CD4 cell count [14],
and has highlighted a need for simpler CD4 testing meth-
ods. However, in countries with constrained resources,
and increasing decentralisation of services, the current
available technologies make it unlikely that CD4 testing
will be available in small health centres that are now inte-
gral to ART programmes. Where equipment is available
and CD4 testing is a policy, challenges remain in ensur-
ing no interruptions in the supply of reagents, power sup-
ply and trained technicians. In many aspects the ART
Clinic in Karonga operated like any other district ART
clinic in Malawi, characteristic of the simplified public
health approach established by the Malawi Ministry of
Health [15], furthermore outcomes of those who started
ART at Karonga [16] were not significantly different to
those reported from other clinics [17-19]. The results of
this study are therefore generalisable to other clinics
in similar contexts.
W ef o u n dt h a t5 8 %o fd e f a u l t e r sf o l l o w e du pi nt h e
community had died; 60% of whom died before their
initiation appointment. This high level of pre-treatment
mortality is consistent with findings from a South African
study [20], and emphasize the need for priority initiation
and improved availability of key drugs and clinical man-
agement. However, the proportion of individuals in
WHO stage 4 at screening (55%), is higher than reported
in established ART clinics in rural Malawi for the same
period [21] and more recently [22]. Our study population
included HIV positive people who may have been eligible
for some time but had no local access to ART previously.
A m o n gt h o s ef o u n dt ob ea l i v ea tt h et r a c k i n gv i s i t ,
the most frequently reported barrier to returning to the
clinic was cost of transport, a barrier that has also been
documented in centralised prevention of mother-to-
child transmission and ART programmes elsewhere in
rural Malawi [23,24]. These reports suggest that targeted
support may be beneficial at screening visits but pov-
erty-related barriers are likely to be persistent and also
affect long-term retention on ART. More recent devol-
vement of ART initiation from the district hospital
alone to additional rural hospitals within the district,
resulting in shorter distances for individuals to attend
an ART clinic is likely to have eased this barrier.
Several other ART-eligible patients alive at the tracking
visit cited lack of a suitable guardian/buddy as a barrier
to ART. The policy of requiring a guardian to accompany
individuals until they are established on ART remains
part of the national programme in Malawi. This policy is
based on experience of the national TB treatment pro-
gramme and its impact has not been formally evaluated
in the ART programme. In a society where literacy and
education levels are low, a guardian also receives the
treatment-related education and can support the indivi-
dual, remind them to take drugs, help with drug taking,
attend clinic on their behalf etc. In Malawi, hospital
patients are expected to come with a guardian to provide
basic nursing care - washing, feeding, toileting etc. In the
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physical help to get to clinic, and care whilst at the clinic.
ART programme success is currently measured as the
proportion continuing to receive ART among those who
started treatment and survived. However we have shown
that there are many patients who are considered eligible
for ART, but do not start treatment. For many of these
patients the reason for not receiving ART was that they
had died. These early deaths are not included in routine
programme statistics. Considering all those who are eli-
gible for ART as a denominator for programme indica-
tors would help to highlight this vulnerable group, in
order to identify new opportunities for further improv-
ing ART programmes.
Additional material
Additional file 1: Appendix 1: Clinical questionnaire.T h i s
questionnaire was used to collect clinical data at screening visits in the
Karonga ART clinic. The section ‘Findings’ is a clinical tool/checklist of
symptoms and signs that we developed in order to lead the clinician
systematically through all the AIDS defining criteria when ascertaining
ART eligibility. In Karonga district, in common with most areas of Malawi,
diagnostic facilities are limited and it is not possible to obtain
microbiological, histological or imaging support for WHO Stage 4
diagnoses.
Acknowledgements
The authors thank the women and men who agreed to participate in this
study, the ART clinic staff & the field team. They would also like to thank the
National Health Sciences Research Committee of Malawi and the Malawi
Ministry of Health for their continued support. The Karonga Prevention
Study is supported by the Wellcome Trust, UK, and the British Leprosy Relief
Association (LEPRA). This study was in part supported by the World Health
Organization, through the Malawi National AIDS Commission. McGrath was
supported by the Wellcome Trust, UK (WT083495MA).
Author details
1London School of Hygiene and Tropical Medicine, London, UK.
2Africa
Centre for Health and Population Studies, University of KwaZulu Natal,
Mtubatuba, South Africa.
3HIV Department, Ministry of Health, Lilongwe,
Malawi.
4Karonga Prevention Study, Chilumba, Malawi.
5Karonga District
Hospital, Karonga, Malawi.
Authors’ contributions
This paper was written by NM, JRG, KK, AJ, PEMF and ACC. NM, JRG, JS, KK,
AJ, FrM and ACC contributed to the conception and design of the study.
NM, JS, KK, AJ, FrM, MN, HM, FiM, VM, LM and ACC acquired data or actively
participated in data management activities. NM performed the statistical
analysis. NM, JRG and ACC drafted the report, and all co-authors (except for
the late FrM) revised the manuscript. NM, AJ, FrM and ACC, supported by
JRG and PEMF, obtained funding for the study.
Competing interests
The authors declare that they have no competing interests.
Received: 30 April 2010 Accepted: 12 October 2010
Published: 12 October 2010
References
1. UNAIDS/WHO: Annex 1: country profiles. 2006 report on the Global AIDS
epidemic Geneva, Switzerland 2006.
2. Libamba E, Makombe SD, Harries AD, Schouten EJ, Yu JK, Pasulani O,
Mhango E, Aberle-Grasse J, Hochgesang M, Limbambala E, et al: Malawi’s
contribution to “3b y5 ”: achievements and challenges. Bull World Health
Organ 2007, 85:156-160.
3. Libamba E, Makombe S, Harries AD, Chimzizi R, Salaniponi FM, Schouten EJ,
Mpazanje R: Scaling up antiretroviral therapy in Africa: learning from
tuberculosis control programmes–the case of Malawi. Int J Tuberc Lung
Dis 2005, 9:1062-1071.
4. Harries AD, Makombe SD, Schouten EJ, Ben Smith A, Jahn A: Different
delivery models for antiretroviral therapy in sub-Saharan Africa in the
context of ‘universal access’. Trans R Soc Trop Med Hyg 2008, 102:310-311.
5. Department of HIV and AIDS MoH: Quarterly Report of the Antiretroviral
Treatment Programme in Malawi, With Results up to 31 December 2008
Lilongwe, Malawi 2008.
6. Tayler-Smith K, Zachariah R, Massaquoi M, Manzi M, Pasulani O, van den AT,
Bemelmans M, Bauernfeind A, Mwagomba B, Harries AD: Unacceptable
attrition among WHO stages 1 and 2 patients in a hospital-based
setting in rural Malawi: can we retain such patients within the general
health system? Trans R Soc Trop Med Hyg 2010, 104:313-319.
7. Bizuwork T, Makombe SD, Kamoto K, Hochgesang M, Harries AD: An audit
of how patients get on to antiretroviral therapy in Malawi, and the
weight gain they experience in the first six months. Malawi Medical
Journal 2007, 19:104-106.
8. WHO International Classification of Functioning, Disability and Health.
2010.
9. Bassett IV, Wang B, Chetty S, Mazibuko M, Bearnot B, Giddy J, Lu Z,
Losina E, Walensky RP, Freedberg KA: Loss to care and death before
antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic
Syndr 2009, 51:135-139.
10. Harries AD, Rusen ID, Chiang CY, Hinderaker SG, Enarson DA: Registering
initial defaulters and reporting on their treatment outcomes. Int J Tuberc
Lung Dis 2009, 13:801-803.
11. Glynn JR, Warndorff DK, Fine PE, Munthali MM, Sichone W, Ponnighaus JM:
Measurement and determinants of tuberculosis outcome in Karonga
District, Malawi. Bull World Health Organ 1998, 76:295-305.
12. Karcher H, Omondi A, Odera J, Kunz A, Harms G: Risk factors for treatment
denial and loss to follow-up in an antiretroviral treatment cohort in
Kenya. Trop Med Int Health 2007, 12:687-694.
13. Thai S, Koole O, Un P, Ros S, De Munter P, Van Damme W, Jacques G,
Colebunders R, Lynen L: Five-year experience with scaling-up access to
antiretroviral treatment in an HIV care programme in Cambodia. Trop
Med Int Health 2009, 14:1048-1058.
14. McGrath N, Kranzer K, Saul J, Crampin AC, Malema S, Kachiwanda L, Zaba B,
Jahn A, Fine PE, Glynn JR: Estimating the need for antiretroviral treatment
and an assessment of a simplified HIV/AIDS case definition in rural
Malawi. AIDS 2007, 21(Suppl 6):S105-S113.
15. Harries AD, Schouten EJ, Libamba E: Scaling up antiretroviral treatment in
resource-poor settings. Lancet 2006, 367:1870-1872.
16. HIV Unit: Ministry of Health Malawi ART Public Sector 2006 Quarter 2.
2010.
17. Chen SC, Yu JK, Harries AD, Bong CN, Kolola-Dzimadzi R, Tok TS, King CC,
Wang JD: Increased mortality of male adults with AIDS related to poor
compliance to antiretroviral therapy in Malawi. Trop Med Int Health 2008,
13:513-519.
18. Yu JK, Chen SC, Wang KY, Chang CS, Makombe SD, Schouten EJ,
Harries AD: True outcomes for patients on antiretroviral therapy who are
“lost to follow-up” in Malawi. Bull World Health Organ 2007, 85:550-554.
19. Yu JK, Tok TS, Tsai JJ, Chang WS, Dzimadzi RK, Yen PH, Makombe SD,
Nkhata A, Schouten EJ, Kamoto K, et al: What happens to patients on
antiretroviral therapy who transfer out to another facility? PLoS One
2008, 3:e2065.
20. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R: Determinants of
mortality and nondeath losses from an antiretroviral treatment service
in South Africa: implications for program evaluation. Clin Infect Dis 2006,
43:770-776.
21. Zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Arnould L, Makombe S,
Harries AD: Risk factors for high early mortality in patients on
antiretroviral treatment in a rural district of Malawi. AIDS 2006,
20:2355-2360.
McGrath et al. BMC Public Health 2010, 10:601
http://www.biomedcentral.com/1471-2458/10/601
Page 7 of 822. Zachariah R, Harries K, Moses M, Manzi M, Line A, Mwagomba B, Harries AD:
Very early mortality in patients starting antiretroviral treatment at
primary health centres in rural Malawi. Trop Med Int Health 2009,
14:713-721.
23. Bwirire LD, Fitzgerald M, Zachariah R, Chikafa V, Massaquoi M, Moens M,
Kamoto K, Schouten EJ: Reasons for loss to follow-up among mothers
registered in a prevention-of-mother-to-child transmission program in
rural Malawi. Trans R Soc Trop Med Hyg 2008, 102:1195-1200.
24. Zachariah R, Harries AD, Manzi M, Gomani P, Teck R, Phillips M, Firmenich P:
Acceptance of anti-retroviral therapy among patients infected with HIV
and tuberculosis in rural Malawi is low and associated with cost of
transport. PLoS One 2006, e121.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2458/10/601/prepub
doi:10.1186/1471-2458-10-601
Cite this article as: McGrath et al.: What happens to ART-eligible
patients who do not start ART? Dropout between screening and ART
initiation: a cohort study in Karonga, Malawi. BMC Public Health 2010
10:601.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
McGrath et al. BMC Public Health 2010, 10:601
http://www.biomedcentral.com/1471-2458/10/601
Page 8 of 8